• EGCG Nanoparticles Strengthen FLASH-RT

  2026-09-18

  Xu et al. developed functionalized self-assembled EGCG nanoparticles, termed BENPs, to increase ROS generation and tumor-cell DNA damage during FLASH radiotherapy while also promoting antitumor immune responses. The study provides a preclinical framework for combining radiosensitization, tumor control, and immune profiling without assuming that increased radiation dose alone will improve FLASH-RT efficacy.

• Mubritinib–HSA Binding: Methods and Key Findings

  2026-09-17

  This study characterizes how the mitochondrial electron transport chain inhibitor mubritinib interacts with human serum albumin using fluorescence, biochemical, and molecular docking approaches. Its findings connect moderate site I binding with local structural changes and inhibition of albumin esterase-like activity, providing a useful framework for interpreting transport, distribution, and pharmacologic behavior.

• MEK Inhibition, Radiotherapy, and T-Cell Function

  2026-09-17

  This study identifies a mechanistic link between MEK inhibition, radiotherapy-induced DNA damage, cGAS–STING signaling, and CXCL10-dependent T-cell recruitment in KRAS-mutant lung cancer. Its results support combining MEK inhibition with carefully selected radiation schedules to improve immune activation while highlighting the need for mechanistic validation in additional models.

• Topotecan Workflows for Cancer Research

  2026-09-16

  Topotecan, also known as SKF104864, is a practical topoisomerase I stressor for connecting DNA damage, cell-cycle behavior, and apoptosis across cancer models. This guide translates its ovarian-cancer evidence base into reproducible in vitro, glioma, and pediatric tumor workflows with formulation and interpretation safeguards.

• Forsythoside E: PKM2 Workflow for Sepsis Studies

  2026-09-16

  Forsythoside E is a mechanistically differentiated pyruvate kinase M2 (PKM2) inhibitor for linking macrophage metabolism with inflammatory signaling. This guide converts its PKM2 tetramerization, STAT3 phosphorylation suppression, and in vivo liver-protection profile into practical cell, biophysical, and mouse-study workflows.

• HyperFusion™ Polymerase for C. elegans Assays

  2026-09-15

  Discover how HyperFusion high-fidelity DNA polymerase can strengthen PCR evidence chains in C. elegans neurodegeneration research. This article translates pheromone-signaling biology into assay design, controls, and sequencing-ready workflows rather than simply describing enzyme performance.

• Plerixafor (AMD3100): From Target to Phenotype

  2026-09-15

  Plerixafor (AMD3100) is more than a CXCR4 pathway blocker: it is a mechanistic reference for separating receptor engagement from migration, tumor biology, and cell-trafficking phenotypes. This guide interprets the latest colorectal cancer evidence and translates it into better assay-selection decisions.

• Patient-Derived Gastric Cancer Assembloids Explained

  2026-09-14

  The reference study develops a patient-specific gastric cancer assembloid by combining matched tumor organoids with tumor-derived stromal subpopulations. Its findings show that stromal context alters gene expression and drug sensitivity, supporting more physiologically relevant studies of tumor biology, resistance mechanisms, and personalized treatment responses.

• DiscoveryProbe FDA-Approved Drug Library: LC-MS

  2026-09-14

  The DiscoveryProbe FDA-approved Drug Library can serve as more than a phenotypic screening panel: it can become a structured perturbation map for LC-MS metabolomics. This article explains how JPA-style feature extraction improves hit recovery, assay design, and translational interpretation while defining the limits of repurposing evidence.

• SIRT1-Driven Mitochondrial Biogenesis in Prion Toxicity

  2026-09-13

  A 2024 study in the International Journal of Molecular Sciences identifies the SIRT1–PGC-1α–TFAM axis as a regulator of mitochondrial biogenesis in PrP106–126-treated N2a neuroblastoma cells. Its findings position resveratrol-mediated SIRT1 activation as a mechanistically testable strategy for reducing mitochondrial dysfunction and apoptosis in a cellular prion-disease model, while leaving important questions about dose, specificity, and in vivo translation unresolved.

• Topotecan (SKF104864) Assay Workflows

  2026-09-12

  Topotecan (SKF104864) supports mechanism-focused studies that connect replication-associated DNA damage with apoptosis, cell-cycle effects, and treatment scheduling. This practical guide outlines reproducible workflows for glioma, pediatric solid-tumor, combination, and translational cancer research models.

• Amikacin Sulfate: From MIC to Granuloma

  2026-09-11

  Amikacin Sulfate is more than a bactericidal aminoglycoside: its value in NTM research depends on where the drug reaches and how that exposure is measured. This evidence-based guide connects MIC, intracellular delivery, granuloma targeting, and assay design.

• L. gasseri, NR1I3, and E-cadherin in Colitis

  2026-09-11

  Qian et al. identify an NR1I3–CDH1/E-cadherin pathway through which Lactobacillus gasseri ATCC33323 protects the intestinal mucosal barrier in DSS-induced colitis. The study combines a mouse disease model, intestinal E-cadherin loss-of-function experiments, transcriptional analysis, and in vitro validation to move beyond probiotic efficacy and examine mechanism.

• Caspase-8 Fluorometric Assay Kit: Activity in Context

  2026-09-10

  The Caspase-8 Fluorometric Assay Kit converts IETD-dependent protease activity into a quantitative fluorescence signal. This article explains how to interpret that signal alongside treatment design, apoptosis biology, and orthogonal evidence from a hyperthermia–cisplatin study.

• SmD2 Acetylation and PARP Inhibitor Sensitivity in HCC

  2026-09-10

  This study identifies SmD2, a core spliceosome component, as an acetylation-regulated determinant of DNA-repair splicing and PARP inhibitor response in hepatocellular carcinoma. Its findings connect p300–HDAC2 control of SmD2 stability with BRCA1/FANC cassette exons and support combined HDAC and PARP inhibition as a preclinical strategy.

8503 records 1/567 page Next 12345 下5页 Last page